Foundation Medicine, Inc. (NASDAQ:FMI) SVP Robert W. Hesslein sold 2,165 shares of Foundation Medicine stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $38.80, for a total value of $84,002.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Robert W. Hesslein also recently made the following trade(s):

  • On Thursday, July 6th, Robert W. Hesslein sold 5,070 shares of Foundation Medicine stock. The shares were sold at an average price of $38.84, for a total value of $196,918.80.

Foundation Medicine, Inc. (FMI) traded up 7.27% during mid-day trading on Thursday, hitting $44.14. The company’s stock had a trading volume of 237,679 shares. The company’s market cap is $1.59 billion. The firm’s 50-day moving average is $39.26 and its 200-day moving average is $37.30. Foundation Medicine, Inc. has a 12-month low of $17.10 and a 12-month high of $44.95.

Foundation Medicine (NASDAQ:FMI) last issued its quarterly earnings data on Tuesday, August 1st. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($1.08) by ($0.16). Foundation Medicine had a negative net margin of 131.79% and a negative return on equity of 109.63%. The business had revenue of $35.00 million for the quarter, compared to analysts’ expectations of $34.94 million. During the same quarter in the prior year, the company posted ($0.84) EPS. The business’s revenue for the quarter was up 23.9% on a year-over-year basis. Analysts predict that Foundation Medicine, Inc. will post ($4.67) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.watchlistnews.com/foundation-medicine-inc-fmi-svp-robert-w-hesslein-sells-2165-shares-of-stock/1610636.html.

Several institutional investors and hedge funds have recently modified their holdings of the company. Alliancebernstein L.P. lifted its holdings in shares of Foundation Medicine by 38.7% during the 1st quarter. Alliancebernstein L.P. now owns 788,860 shares of the company’s stock valued at $25,441,000 after purchasing an additional 220,236 shares during the last quarter. Oppenheimer & Co. Inc. lifted its holdings in shares of Foundation Medicine by 1.3% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 684,090 shares of the company’s stock valued at $27,192,000 after purchasing an additional 9,050 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Foundation Medicine by 8.2% during the 2nd quarter. Vanguard Group Inc. now owns 631,339 shares of the company’s stock valued at $25,096,000 after purchasing an additional 47,843 shares during the last quarter. Lord Abbett & CO. LLC lifted its holdings in shares of Foundation Medicine by 146.0% during the 2nd quarter. Lord Abbett & CO. LLC now owns 579,225 shares of the company’s stock valued at $23,024,000 after purchasing an additional 343,770 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of Foundation Medicine by 124.2% during the 2nd quarter. State Street Corp now owns 526,775 shares of the company’s stock valued at $20,947,000 after purchasing an additional 291,815 shares during the last quarter. Hedge funds and other institutional investors own 31.84% of the company’s stock.

A number of brokerages have issued reports on FMI. BidaskClub upgraded Foundation Medicine from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. Zacks Investment Research lowered Foundation Medicine from a “hold” rating to a “sell” rating in a report on Tuesday. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. Foundation Medicine currently has a consensus rating of “Hold” and a consensus target price of $35.00.

Foundation Medicine Company Profile

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.